PSTX Poseida Company Assets

PSTX (Poseida) - company brandmark

This chart illustrates that the market valuation of Poseida Therapeutics (PSTX) total assets is 297.99. Poseida Therapeutics (PSTX) focuses on developing affordable non-viral gene editing methods to combat tumors. Operational efficiency is maintained by outsourcing manufacturing processes and testing to third-party contractors. Profit stability is ensured through a calibrated transportation system for frozen components via a network of specialized centers.

PSTX - Poseida Therapeutics, Inc. Company Total Assets over the range 07/04/2022 - 01/18/2025

Analytical breakdowns and data insights for company Poseida (PSTX)

- stock quotes and analyst forecast:
Share Price poseida.com|PSTX - Price Target Chart
- market capitalization data:
Market Value Poseida Corp|PSTX - Total Company Value
- balance sheet equity data:
Equity per Share Poseida Therapeutics|PSTX - Book Capitalization|Market Cap to Net Assets Ratio poseida.com|PSTX - Aggregate Company Assets
- debt and liquidity details:
Debt to Capital Poseida Therapeutics|PSTX - Long-Term Debt to Equity|Short-Term Debt to Equity Poseida Corp|PSTX - Company Debts|Debts to Book Value Poseida Corp|PSTX - Company Long-Term Debts|Short-Term Indebtedness Poseida Therapeutics|Immediate Liquidity poseida.com
- earnings and market ratios statistics:
PSTX - Net Income
Basic company analysis:PSTX poseida.com
Signature product of Poseida Corp

By scaling the development of allogeneic CAR-T therapies in partnership with Roche, Poseida Therapeutics (PSTX) is accumulating resources, the dynamics of which in the total assets forecast reflect the aggregate of capital and liabilities reverse-calculated via ROA. This indicator allows for the real-time assessment of structural shifts in the company's assets, which is critical for evaluating the issuer's ability to exercise pricing power as healthcare costs decline.

Direct competitors

Total Business Assets LEGN|Aggregate Company Assets Sana Biotechnology, Inc.|Company Assets Autolus Therapeutics PLC AUTL|Aggregate Company Assets Allogene Therapeutics Inc (ALLO)|Selecta Biosciences Inc. - Total Business Assets|Company Total Assets CLLS (Cellectis)|CRBU - Cumulative Company Assets|TIL - Aggregate Company Assets|Company Assets Genenta Science S.p.A.|centurytx.com (IPSC) - Aggregate Company Assets|JSPR (Jasper Therapeutics, Inc.) - Aggregate Company Assets|Aggregate Company Assets Senti Bio|Company Assets Adaptimmune Therapeutics PLC ADAP|Company Total Assets CERO|alaunos.com (TCRT) - Company Balance Sheet Assets|Achilles Therapeutics plc - Cumulative Company Assets|CARGO Therapeutics, Inc (CRGX) - Company Assets|TSVT: Cumulative Company Assets|Aggregate Asset Value GRCL (gracellbio.com)